RxDoctor Payments DataLook up a doctor →

Srinivasa Potluri, MD

Interventional Cardiology · Plano, TXNPI 1295783736

Payments from drug & device makers

$5,142,410in general payments, 2019–2025

Across 1,735 payments — averaging $2963.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2M
  • Medtronic$1.7M
  • Abbott$783K
  • Shockwave Medical, Inc$284K
  • Terumo Medical Corporation$141K
  • Siemens Medical Solutions USA, Inc.$63K
  • plus $232K from 47 others

What the payments were for

  • Consulting fees$305,81439%
  • Speaking & faculty fees$364,29847%
  • Travel & lodging$56,3117%
  • Food & beverage$54,5657%
  • Entertainment$1030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,142,410 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$316,034
Medicare patients
656
Services billed
3,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$131,989
XareltoRivaroxaban51$58,968
Repatha SureclickEvolocumab43$49,719
EntrestoSacubitril/Valsartan32$49,032
JardianceEmpagliflozin34$42,315
Ranolazine ErRanolazine45$7,781
Rosuvastatin Calcium229$3,700
Metoprolol Succinate224$3,557
ClopidogrelClopidogrel Bisulfate312$3,505
Ezetimibe97$2,446
Atorvastatin Calcium207$1,784
Losartan Potassium109$1,145
Amlodipine Besylate136$1,143
Flecainide Acetate19$916
Carvedilol91$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$131,989112 claims
Johnson & JohnsonXarelto$24,185$58,96851 claims
NovartisEntresto$46$49,03232 claims
Boehringer IngelheimJardiance$34$42,31534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →